Resultados de procura - Xiao-Yan Ma

  • Mostrando 1 - 9 Resultados de 9
Limitar resultados
  1. 1
    Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer

    Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer por Li Liao, Yin-Ling Zhang, Ling Deng, Chao Chen, Xiao-Yan Ma, Lisa Andriani, Shao‐Ying Yang, Shu‐Yuan Hu, Fang-Lin Zhang, Zhimin Shao, Da‐Qiang Li

    Publicado 2022
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  2. 2
    Dynamic SUMOylation of MORC2 orchestrates chromatin remodelling and DNA repair in response to DNA damage and drives chemoresistance in breast cancer

    Dynamic SUMOylation of MORC2 orchestrates chromatin remodelling and DNA repair in response to DNA damage and drives chemoresistance in breast cancer por Fanglin Zhang, Shao‐Ying Yang, Li Liao, Tai‐Mei Zhang, Yinling Zhang, Shu‐Yuan Hu, Ling Deng, Min-Ying Huang, Lisa Andriani, Xiao-Yan Ma, Zhimin Shao, Da‐Qiang Li

    Publicado 2023
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  3. 3
    SF3A2 promotes progression and cisplatin resistance in triple-negative breast cancer via alternative splicing of MKRN1

    SF3A2 promotes progression and cisplatin resistance in triple-negative breast cancer via alternative splicing of MKRN1 por Ling Deng, Li Liao, Yin‐Ling Zhang, Shao‐Ying Yang, Shu‐Yuan Hu, Lisa Andriani, Yun-Xiao Ling, Xiao-Yan Ma, Fang-Lin Zhang, Zhi‐Ming Shao, Da‐Qiang Li

    Publicado 2024
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models

    Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models por Zebin Wang, Kaiming Sun, Yonghong Xiao, Bin Feng, Keith Mikule, XiaoYan Ma, Ningping Feng, Christopher P. Vellano, Lorenzo Federico, Joseph R. Marszalek, Gordon B. Mills, Jeffrey H. Hanke, Sridhar Ramaswamy, Jing Wang

    Publicado 2019
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    In vivo multidimensional CRISPR screens identify <i>Lgals2</i> as an immunotherapy target in triple-negative breast cancer

    In vivo multidimensional CRISPR screens identify <i>Lgals2</i> as an immunotherapy target in triple-negative breast cancer por Peng Ji, Yue Gong, Ming‐Liang Jin, Huailiang Wu, Linwei Guo, Yu‐Chen Pei, Wen-Jun Chai, Yi‐Zhou Jiang, Yin Liu, Xiao-Yan Ma, Gen-Hong Di, Xin Hu, Zhi‐Ming Shao

    Publicado 2022
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer

    CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer por Song‐Yang Wu, Si-Wei Zhang, Ding Ma, Yi Xiao, Yin Liu, Li Chen, Xiao-Qing Song, Xiao-Yan Ma, Ying Xu, Wen-Jun Chai, Xi Jin, Zhi-Ming Shao, Yi‐Zhou Jiang

    Publicado 2023
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial

    Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial por Song‐Yang Wu, Ying Xu, Li Chen, Lei Fan, Xiao-Yan Ma, Shen Zhao, Xiao-Qing Song, Xin Hu, Wentao Yang, Wen-Jun Chai, Xiaomao Guo, Xi-Zi Chen, Yanhui Xu, Xiaoyu Zhu, Jianjun Zou, Zhonghua Wang, Yi‐Zhou Jiang, Zhi-Ming Shao

    Publicado 2022
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  8. 8
    Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

    Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial por Li Chen, Yi‐Zhou Jiang, Song‐Yang Wu, Jiong Wu, Gen‐Hong Di, Guang‐Yu Liu, Ke‐Da Yu, Lei Fan, Junjie Li, Yifeng Hou, Zhen Hu, Canming Chen, Xiaoyan Huang, A‐Yong Cao, Xin Hu, Shen Zhao, Xiao-Yan Ma, Ying Xu, Xiangjie Sun, Wen-Jun Chai, Xiaomao Guo, Xizi Chen, Yanhui Xu, Xiaoyu Zhu, Jianjun Zou, Wentao Yang, Zhonghua Wang, Zhi‐Ming Shao

    Publicado 2022
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  9. 9
    Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

    Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy por Christopher P. Vellano, Michael G. White, Miles C. Andrews, Manoj Chelvanambi, Russell G. Witt, Joseph R. Daniele, Mark Titus, Jennifer L. McQuade, Fabio Conforti, Elizabeth M. Burton, Matthew Lastrapes, Gabriel O Ologun, Alexandria P. Cogdill, Golnaz Morad, Peter A. Prieto, Alexander J. Lazar, Yanshuo Chu, Guangchun Han, M.A. Wadud Khan, Beth A. Helmink, Michael A. Davies, Rodabe N. Amaria, Jeffrey J. Kovacs, Scott E. Woodman, Sapna P. Patel, Patrick Hwu, Michael Peoples, Jeffrey E. Lee, Zachary A. Cooper, Haifeng Zhu, Guang R. Gao, Hiya Banerjee, Mike Lau, Jeffrey E. Gershenwald, Anthony Lucci, Emily Z. Keung, Merrick I. Ross, Laura Pala, Eleonora Pagan, Rossana Lazcano Segura, Qian Liu, Mikayla Borthwick, Eric Lau, Melinda S. Yates, Shannon N. Westin, Khalida Wani, Michael T. Tetzlaff, Lauren E. Haydu, Mikhila Mahendra, Xiao-Yan Ma, Christopher J. Logothetis, Zachary Kulstad, Sarah Johnson, Courtney W. Hudgens, Ningping Feng, Lorenzo Federico, Georgina V. Long, P. Andrew Futreal, Swathi Arur, Hussein A. Tawbi, Amy E. Moran, Linghua Wang, Timothy P. Heffernan, Joseph R. Marszalek, Jennifer A. Wargo

    Publicado 2022
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: